BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37089387)

  • 21. Merlin immunohistochemistry is useful in diagnosis of tumours within the spectrum of biphasic hyalinizing psammomatous renal cell carcinoma.
    Collins K; Hwang M; Antic T; Paintal A; Argani P; Matoso A; Gopinath A; Baskovich B; Mehra R; Williamson SR; Idrees MT; Barletta JA; Anderson WJ; Hirsch MS; Hornick JL; Acosta AM
    Histopathology; 2022 Nov; 81(5):577-586. PubMed ID: 35971742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Morphologic and Immunohistochemical Characteristics of Fluorescent In Situ Hybridization Confirmed TFE3-Gene Fusion Associated Renal Cell Carcinoma: A Single Institutional Cohort.
    Akgul M; Saeed O; Levy D; Mann SA; Cheng L; Grignon DJ; Eble JN; Idrees MT
    Am J Surg Pathol; 2020 Nov; 44(11):1450-1458. PubMed ID: 32701515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma].
    Yu YF; He SM; Wu YC; Xiong SW; Shen Q; Li YY; Yang F; He Q; Li XS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 53(4):640-646. PubMed ID: 34393221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemistry for TFE3 lacks specificity and sensitivity in the diagnosis of TFE3-rearranged neoplasms: a comparative, 2-laboratory study.
    Sharain RF; Gown AM; Greipp PT; Folpe AL
    Hum Pathol; 2019 May; 87():65-74. PubMed ID: 30851332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification.
    Rizzo M; Caliò A; Brunelli M; Pezzicoli G; Ganini C; Martignoni G; Camillo P
    Cancer Treat Rev; 2023 May; 116():102558. PubMed ID: 37060647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
    Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
    Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clear cell renal cell carcinoma with focal psammomatous calcifications: a rare occurrence mimicking translocation carcinoma.
    Sangoi AR; Al-Obaidy KI; Cheng L; Kao CS; Chan E; Sadasivan S; Levin AM; Alvarado-Cabrero I; Kunju LP; Mehra R; Mannan R; Wang X; Dhillon J; Tretiakova M; Smith SC; Hes O; Williamson SR
    Histopathology; 2023 Apr; 82(5):684-690. PubMed ID: 36564980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service.
    Green WM; Yonescu R; Morsberger L; Morris K; Netto GJ; Epstein JI; Illei PB; Allaf M; Ladanyi M; Griffin CA; Argani P
    Am J Surg Pathol; 2013 Aug; 37(8):1150-63. PubMed ID: 23715164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Re-evaluation of histological type by immunohistochemical and genetic study of transcription factors (TFE3 and TFEB) of VHL gene mutation-negative clear cell renal cell carcinoma and other special types of renal tumor.
    Kuroda N; Kawada C; Tamura K; Hiroi M; Hes O; Michal M; Wada Y; Inoue K; Ohara M; Mizuno K; Shuin T; Lee GH
    Med Mol Morphol; 2011 Mar; 44(1):46-51. PubMed ID: 21424937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Xp11 translocation renal cell carcinoma and clear cell renal cell carcinoma with TFE3 strong positive immunostaining: morphology, immunohistochemistry, and FISH analysis.
    Yang B; Duan H; Cao W; Guo Y; Liu Y; Sun L; Zhang J; Sun Y; Ma Y
    Mod Pathol; 2019 Oct; 32(10):1521-1535. PubMed ID: 31175325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays.
    Skala SL; Xiao H; Udager AM; Dhanasekaran SM; Shukla S; Zhang Y; Landau C; Shao L; Roulston D; Wang L; Siddiqui J; Cao X; Magi-Galluzzi C; Zhang M; Osunkoya AO; Smith SC; McKenney JK; Betz BL; Myers JL; Chinnaiyan AM; Tomlins SA; Mehra R
    Mod Pathol; 2018 Jan; 31(1):179-197. PubMed ID: 28840857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel VCP::TFE3 gene fusion resulting from t(X;9)(p11.23;p13.3) chromosome translocation in TFE3 rearranged renal cancer cell carcinoma.
    Kuentz MA; Blons H; Gimenez-Roqueplo AP; Just PA; Laurent-Puig P; Mejean A; Oudard S; Verkarre V
    Genes Chromosomes Cancer; 2023 Jun; 62(6):361-366. PubMed ID: 36695651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microphthalmia family of transcription factors associated renal cell carcinoma.
    Xie L; Zhang Y; Wu CL
    Asian J Urol; 2019 Oct; 6(4):312-320. PubMed ID: 31768316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ALK-rearranged renal cell carcinoma (ALK-RCC): Evaluation of histomorphological and immunohistochemical features by analysis of 276 renal cell carcinoma cases in Turkey.
    Doğan K; Onder E
    Pathol Res Pract; 2024 Jan; 253():154951. PubMed ID: 38039739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of ALK-rearranged renal cell carcinomas with a focus on clinical and pathobiological aspects.
    Kuroda N; Sugawara E; Kusano H; Yuba Y; Yorita K; Takeuchi K
    Pol J Pathol; 2018; 69(2):109-113. PubMed ID: 30351856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Renal cell carcinoma with t(6;11)(p21.2;q13)/MALAT1-TFEB fusion: a clinical and pathological analysis].
    Xia Q; Shi S; Shen Q; Wei X; Wang X; Ma H; Lu Z; Zhou X; Rao Q
    Zhonghua Bing Li Xue Za Zhi; 2015 Dec; 44(12):895-9. PubMed ID: 26888508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathological features and prognosis of TFE3-positive renal cell carcinoma.
    Dong X; Chen Y; Pan J; Ma W; Zhou P; Chen M; Guo H; Gan W
    Front Oncol; 2022; 12():1017425. PubMed ID: 36276115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene fusion analysis in renal cell carcinoma by FusionPlex RNA-sequencing and correlations of molecular findings with clinicopathological features.
    Tretiakova MS; Wang W; Wu Y; Tykodi SS; True L; Liu YJ
    Genes Chromosomes Cancer; 2020 Jan; 59(1):40-49. PubMed ID: 31400230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ALK-rearranged renal cell carcinomas in children.
    Cajaiba MM; Jennings LJ; Rohan SM; Perez-Atayde AR; Marino-Enriquez A; Fletcher JA; Geller JI; Leuer KM; Bridge JA; Perlman EJ
    Genes Chromosomes Cancer; 2016 May; 55(5):442-51. PubMed ID: 26773439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The classification of pediatric and young adult renal cell carcinomas registered on the children's oncology group (COG) protocol AREN03B2 after focused genetic testing.
    Cajaiba MM; Dyer LM; Geller JI; Jennings LJ; George D; Kirschmann D; Rohan SM; Cost NG; Khanna G; Mullen EA; Dome JS; Fernandez CV; Perlman EJ
    Cancer; 2018 Aug; 124(16):3381-3389. PubMed ID: 29905933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.